BriaCell Stock Analysis

BCTX
 Stock
  

USD 5.86  0.19  3.14%   

The small slide in market price for the last few months could raise concerns from investors as the firm is trading at a share price of 5.86 on 452,700 in volume. The company directors and management did not add much value to BriaCell Therapeutics investors in August. However, diversifying your holdings with BriaCell Therapeutics Corp or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.84. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from BriaCell Therapeutics partners.
Continue to Trending Equities.
  
The BriaCell Therapeutics stock analysis report makes it easy to digest most publicly released information about BriaCell Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. BriaCell Stock analysis module also helps to analyze the BriaCell Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

BriaCell Stock Analysis Notes

About 25.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.68. Some equities with similar Price to Book (P/B) outperform the market in the long run. BriaCell Therapeutics recorded a loss per share of 0.29. The entity had not issued any dividends in recent years. The firm had a split on the 2nd of January 2020. BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada. BriaCell Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people. For more info on BriaCell Therapeutics Corp please contact the company at 604 921 1810 or go to https://www.briacell.com.

BriaCell Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. BriaCell Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding BriaCell Therapeutics Corp or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
BriaCell Therapeutics generated a negative expected return over the last 90 days
BriaCell Therapeutics has high historical volatility and very poor performance
BriaCell Therapeutics has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (13.81 M).
BriaCell Therapeutics Corp currently holds about 44.53 M in cash with (11.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.87.
Roughly 25.0% of the company shares are held by company insiders
Latest headline from investingnews.com: Merck Animal Health to Acquire Vence - Investing News Network

BriaCell Therapeutics Upcoming and Recent Events

Earnings reports are used by BriaCell Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to BriaCell Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report30th of March 2022
Next Financial Report5th of July 2022
Next Fiscal Quarter End31st of January 2022
Next Fiscal Year End27th of October 2022
Last Quarter Report31st of October 2021
Last Financial Announcement31st of January 2021

BriaCell Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. BriaCell Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that BriaCell Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial BriaCell Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
14th of September 2022
Financial Statements and Exhibits. Regulation FD Disclosure
View
4th of August 2022
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
1st of August 2022
Unclassified Corporate Event
View
18th of July 2022
Other Events
View
5th of July 2022
Other Events
View
29th of June 2022
Other Events
View
24th of June 2022
Other Events
View
13th of June 2022
Other Events
View

BriaCell Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as BriaCell Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BriaCell Therapeutics Corp backward and forwards among themselves. BriaCell Therapeutics' institutional investor refers to the entity that pools money to purchase BriaCell Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Kj Harrison Partners IncCommon Shares1.6 M9.2 M
Susquehanna International Group LlpCall Options840 K4.8 M
Lynwood Capital Management IncCommon Shares615 K3.5 M
Sabby Management LlcPut OptionsK2.9 M
Wasatch Advisors IncCommon Shares356.5 K2.1 M
Murchinson LtdWarrants526.2 K1.4 M
Redmond Asset Management LlcCommon Shares137.9 K796 K
Sabby Management LlcCommon Shares57.6 K332 K
Jane Street Group LlcCommon Shares50.3 K290 K
Summit Trail Advisors LlcCommon Shares35 K202 K
Note, although BriaCell Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

BriaCell Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 96.27 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BriaCell Therapeutics's market, we take the total number of its shares issued and multiply it by BriaCell Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (23.47) % which means that it has lost $23.47 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (46.36) %, meaning that it created substantial loss on money invested by shareholders. BriaCell Therapeutics management efficiency ratios could be used to measure how well briacell therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 24th of September, BriaCell Therapeutics shows the Mean Deviation of 2.34, risk adjusted performance of 0.0527, and Downside Deviation of 4.68. BriaCell Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for BriaCell Therapeutics Corp, which can be compared to its rivals. Please confirm BriaCell Therapeutics semi deviation, jensen alpha, as well as the relationship between the Jensen Alpha and semi variance to decide if BriaCell Therapeutics is priced correctly, providing market reflects its regular price of 5.86 per share. Given that BriaCell Therapeutics has jensen alpha of 0.1873, we suggest you to validate BriaCell Therapeutics Corp's prevailing market performance to make sure the company can sustain itself at a future point.

BriaCell Therapeutics Price Movement Analysis

null. The output start index for this execution was zero with a total number of output elements of zero. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as BriaCell Therapeutics price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.
.

BriaCell Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BriaCell Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on BriaCell Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BriaCell Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

BriaCell Therapeutics Predictive Daily Indicators

BriaCell Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BriaCell Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

BriaCell Therapeutics Forecast Models

BriaCell Therapeutics time-series forecasting models is one of many BriaCell Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BriaCell Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About BriaCell Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how BriaCell Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling BriaCell shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as BriaCell Therapeutics. By using and applying BriaCell Stock analysis, traders can create a robust methodology for identifying BriaCell entry and exit points for their positions.
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada. BriaCell Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding BriaCell Therapeutics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Equity Valuation Now

   

Equity Valuation

Check real value of public entities based on technical and fundamental data
All  Next Launch Module
Continue to Trending Equities. You can also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for analysis

When running BriaCell Therapeutics price analysis, check to measure BriaCell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BriaCell Therapeutics is operating at the current time. Most of BriaCell Therapeutics' value examination focuses on studying past and present price action to predict the probability of BriaCell Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move BriaCell Therapeutics' price. Additionally, you may evaluate how the addition of BriaCell Therapeutics to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Is BriaCell Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BriaCell Therapeutics. If investors know BriaCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BriaCell Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of BriaCell Therapeutics is measured differently than its book value, which is the value of BriaCell that is recorded on the company's balance sheet. Investors also form their own opinion of BriaCell Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BriaCell Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BriaCell Therapeutics' market value can be influenced by many factors that don't directly affect BriaCell Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BriaCell Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine BriaCell Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BriaCell Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.